KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Restructuring Costs (2018 - 2025)

Arbutus Biopharma (ABUS) has disclosed Restructuring Costs for 6 consecutive years, with $303000.0 as the latest value for Q4 2025.

  • Quarterly Restructuring Costs rose 218.95% to $303000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $25.2 million through Dec 2025, up 577.45% year-over-year, with the annual reading at $12.9 million for FY2025, 247.82% up from the prior year.
  • Restructuring Costs hit $303000.0 in Q4 2025 for Arbutus Biopharma, up from $98000.0 in the prior quarter.
  • In the past five years, Restructuring Costs ranged from a high of $12.4 million in Q1 2025 to a low of $95000.0 in Q4 2024.